Granules India Limited (GRANULES)
Healthcare · Pharmaceuticals & Biotechnology · NSE
· Updated 21 July 2026
₹875.7
↑ 77.09% (1Y)
🎯 Key Takeaways
- Revenue grew 17.7% QoQ to ₹1,138 in Q3FY25.
Market Cap
₹18,243
P/E Ratio
37.2
Div Yield
0.00%
Promoter
0.0%
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,196 | 986 | 1,189 | 1,156 | 1,176 | 1,180 | 967 | 1,138 |
| Operating Profit | 232 | 137 | 215 | 251 | 258 | 261 | 207 | 236 |
| OPM % | 19.1% | 13.9% | 17.9% | 21.7% | 21.8% | 22.0% | 21.0% | 20.2% |
| Net Profit | 120 | 48 | 102 | 126 | 130 | 135 | 97 | 118 |
| EPS | ₹4.94 | ₹1.98 | ₹4.22 | ₹5.18 | ₹5.35 | ₹5.56 | ₹4.01 | ₹4.85 |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
📋 Recent Filings
-
Announcement 21 July 2026Granules India disclosed that India Ratings & Research confirmed no deviation from the stated utilization of proceeds from its INR 1,762.50 crore pref...
-
🟡 Board Meeting 21 July 2026Granules India approved unaudited standalone and consolidated financial results for Q1 FY2026 ending June 30, 2026, along with a limited review report...
-
🔴 Financial Results 21 July 2026Granules India reported Q1FY27 revenue of **₹14,768 crores**, up 22% YoY, with PAT rising 60% to **₹1,800 crores**. EBITDA grew 37% YoY to **₹3,389 cr...
-
🔴 Financial Results 21 July 2026Granules India reported Q1 FY27 revenue of ₹14,768 Mn, up 22% YoY, with PAT rising 60% to ₹1,800 Mn and EBITDA up 37% YoY to ₹3,389 Mn. Gross margin e...
-
Announcement 6 July 2026Granules India announced it secured sole First-to-File status for its ANDA for Sodium Oxybate Extended-Release oral suspension, marking its second suc...
-
Announcement 15 June 2026Granules India announced its tentative schedule for analyst and investor meetings in London on June 23 and 24, 2026, as part of the IIFL Invest India ...
-
Announcement 3 June 2026Granules India announced its US subsidiary Granules Pharmaceuticals received a USFDA Establishment Inspection Report with Voluntary Action Indicated c...
-
Announcement 28 May 2026Granules India announced a tentative analyst and investor meeting scheduled for June 3, 2026, in Hyderabad, with no unpublished price-sensitive inform...
-
🔴 Financial Results 5 May 2026Granules India reported FY26 revenue of **₹53,656 crores**, up 20% YoY, driven by complex generics and CDMO expansion, with gross margin expanding 355...
-
🔴 Corporate Action 29 April 2026Granules India announced that July 30, 2026 will be the record date for shareholders eligible to receive the final dividend for the financial year end...
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-21.
📡 Get AI alerts when GRANULES files new disclosures
Track GRANULES filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GRANULES — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research